Please assess the completion status of the following clinical trial:

Trial Title: ProQuad® Intramuscular vs Subcutaneous

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy participant of either gender,~* Age 12 to 18 months,~* Negative clinical history of measles, mumps, rubella, varicella and zoster,~* Consent form signed by both holders of the parental authority or by the legal representative~* Holder(s) of the the parental authority / legal representative able to understand the protocol requirements and to fill in the Diary Card.~Exclusion Criteria:~* Prior receipt of measles, mumps, rubella and/or varicella vaccine either alone or in any combination,~* Any recent (≤30 days) exposure to measles, mumps, rubella, varicella and/or zoster~* Any recent (≤3 days) history of febrile illness~* Any severe chronic disease,~* Active untreated tuberculosis,~* Known personal history of seizure disorder,~* Any known blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic systems,~* Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection,~* Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity including those resulting from corticosteroid \[any long-term (≥14 days) administration of systemic corticosteroid therapy given daily or on alternate days at high doses (≥2 mg/kg/day prednisone equivalent or ≥20 mg/day if weight more than 10 kg) within the previous 30 days\] or other immunosuppressive therapy,~* Any previous (≤ 150 days) receipt of immune globulin or any blood-derived product or scheduled to be administered through Visit 3,~* Any recent (≤7 days) tuberculin test or scheduled tuberculin test through Visit 3,~* Any recent (≤30 days) receipt of an inactivated or a live vaccine or scheduled vaccination through Visit 3,

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Intramuscular ProQuad® (Type: EXPERIMENTAL): Participants will receive doses of ProQuad® by IM injection on Day 1 and Day 30 into the deltoid muscle perpendicular to the skin, with the first dose in the right arm and the second dose in the left arm.
- Subcutaneous ProQuad® (Type: ACTIVE_COMPARATOR): Participants will receive doses of ProQuad® by SC injection on Day 1 and Day 30 in the deltoid area at a 45° angle to the skin, with the first dose in the right arm and second dose in the left arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).